Regeneron Reports Positive Results of Odronextamab in P-II (ELM-2) Trial for the Treatment of Follicular Lymphoma
Shots:
- Regeneron reveals positive data from P-II (ELM-2) study evaluating safety & efficacy of odronextamab (CD20xCD3 bispecific antibody) in patients with r/r follicular lymphoma (FL)
- The results from prespecified interim analysis with 80 patients (≥12 months follow-up) showed 80% ORR, 73% complete response, mDoR was 23 mos., PFS was 21 mos. & OS was not reached
- Odronextamab is undergoing regulatory review for r/r FL & DLBCL by the US FDA & EMA. It has been granted FTD in the US & ODD in the EU. Odronextamab's potential application for r/r FL & DLBC is in active clinical development. However, full safety and efficacy assessments by regulatory authorities are pending
Ref: Regeneron | Image: Regeneron
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
